Trial · NCT02220894
Adverse events912
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 912
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab | 102 | 636 | 124 |
| other | Anaemia | Blood and lymphatic system disorders | Chemotherapy (SOC Treatment) | 253 | 615 | 332 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 2 | 34 | 2 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab | 10 | 636 | 17 |
| other | Leukopenia | Blood and lymphatic system disorders | Chemotherapy (SOC Treatment) | 35 | 615 | 63 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 1 | 34 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab | 6 | 636 | 9 |
| other | Neutropenia | Blood and lymphatic system disorders | Chemotherapy (SOC Treatment) | 85 | 615 | 177 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 0 | 34 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab | 6 | 636 | 7 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Chemotherapy (SOC Treatment) | 59 | 615 | 86 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 0 | 34 | 0 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab | 37 | 636 | 38 |
| other | Hyperthyroidism | Endocrine disorders | Chemotherapy (SOC Treatment) | 4 | 615 | 4 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab Second Course | 1 | 34 | 1 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab | 76 | 636 | 99 |
| other | Hypothyroidism | Endocrine disorders | Chemotherapy (SOC Treatment) | 10 | 615 | 10 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab Second Course | 3 | 34 | 5 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab | 78 | 636 | 98 |
| other | Constipation | Gastrointestinal disorders | Chemotherapy (SOC Treatment) | 131 | 615 | 168 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02220894/events